CXI Healthcare Technology Group Limited (KOSDAQ:900120)
South Korea
· Delayed Price · Currency is KRW 401.00
-11.00 (-2.67%)
At close: Mar 9, 2026
KOSDAQ:900120 Revenue
CXI Healthcare Technology Group had revenue of 7.38B KRW in the quarter ending December 31, 2025, a decrease of -19.62%. This brings the company's revenue in the last twelve months to 54.16B, down -18.62% year-over-year. In the fiscal year ending June 30, 2025, CXI Healthcare Technology Group had annual revenue of 57.64B, down -16.97%.
Revenue (ttm)
54.16B
Revenue Growth
-18.62%
P/S Ratio
0.22
Revenue / Employee
5.42B
Employees
10
Market Cap
12.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 57.64B | -11.78B | -16.97% |
| Jun 30, 2024 | 69.42B | -2.20B | -3.07% |
| Jun 30, 2023 | 71.62B | -29.76B | -29.35% |
| Jun 30, 2022 | 101.38B | -3.22B | -3.08% |
| Jun 30, 2021 | 104.59B | 41.19B | 64.96% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bioten | 10.71B |
| Future Medicine | 1.00B |
| Kwangdong Healthbio | 38.10B |
| Union Korea Pharm | 33.83B |
| WooGene B&G | 54.77B |
| BIFIDO | 18.65B |
| Daesung Microbiological Labs. | 25.86B |
| ChoA Pharmaceutical Co., LTD. | 60.50B |